ENTA Stock Overview
A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.31 |
| 52 Week High | US$17.80 |
| 52 Week Low | US$8.51 |
| Beta | 0.57 |
| 11 Month Change | -28.38% |
| 3 Month Change | -28.88% |
| 1 Year Change | 3.56% |
| 33 Year Change | -89.29% |
| 5 Year Change | -85.32% |
| Change since IPO | -45.81% |
Recent News & Updates
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Oct 05
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Recent updates
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Oct 05Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Shareholder Returns
| ENTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.1% | -6.5% | -1.0% |
| 1Y | 3.6% | 14.6% | 30.3% |
Return vs Industry: ENTA underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: ENTA underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| ENTA volatility | |
|---|---|
| ENTA Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENTA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 145 | Jay Luly | www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
| ENTA fundamental statistics | |
|---|---|
| Market cap | US$192.39m |
| Earnings (TTM) | -US$115.33m |
| Revenue (TTM) | US$71.96m |
2.7x
P/S Ratio-1.7x
P/E RatioIs ENTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTA income statement (TTM) | |
|---|---|
| Revenue | US$71.96m |
| Cost of Revenue | US$0 |
| Gross Profit | US$71.96m |
| Other Expenses | US$187.29m |
| Earnings | -US$115.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -5.44 |
| Gross Margin | 100.00% |
| Net Profit Margin | -160.27% |
| Debt/Equity Ratio | 117.9% |
How did ENTA perform over the long term?
See historical performance and comparison